CHEMRING GROUP PLC (CHG) — Investment Research Note

Executive summary

Chemring is a UK-listed defence specialist organised into two segments: Countermeasures & Energetics (specialist military explosives, propellants, airborne/naval decoys, precision energetic devices for missiles and space) and Sensors & Information (Roke — AI/ML, electronic warfare, cyber, counter-drone, plus US biological detection). Across the period covered, revenue has grown from £393m (FY21) to £497m (FY25), order book has roughly tripled to a record £1.4bn driven by NATO rearmament, and the group is mid-investment cycle (£44m H1 2026 capex) for capacity that management says will add £100m revenue / £30m operating profit p.a. from 2028 2026-06 H1. The single most important valuation point: today's c.26x trailing P/E already prices in much of that 2028 step-up, leaving limited margin of safety if execution slips on the capacity build or Roke order intake remains soft.

Fair value estimate

Methodology: blended forward earnings multiple (defence-peer P/E) cross-checked against a 2028 normalised earnings view discounted back.
Key assumptions:
- FY26 underlying diluted EPS c.18-19p (H1 2026 was 6.1p, -8% YoY; FY guided unchanged with 70% H2 weighting → consistent with low-end of FY25's 19.4p).
- 2028 step-up: management's £30m op-profit uplift from Energetics expansion + Roke to £250m+ revenue → c.28-32p underlying EPS by FY28.
- Multiple: 18-22x — premium to QinetiQ (~13x), discount to BAE (~20x), reflecting Roke growth optionality but balance-sheet leverage during capex peak.
- 2028 fair value: ~540-660p discounted back ~2.5 years at 9% = ~430-530p.
Fair value range: 425p – 550p per share (implied market cap £1,184m – £1,532m).
Mid: ~488p / £1,358m vs. current £1,420.5m → roughly fair / modestly full, with downside of c.-4% to mid.

Sector context

ICB Industrials / Industrial Goods & Services — confirmed; Chemring sits in defence prime/sub-systems sub-sector.
Quality is above typical industrial peers (strong order cover, niche moats, mid-teen margins); growth is above (defence cycle); leverage is in line (rising into peak capex).
Comparable listed peers: BAE Systems (broad defence), QinetiQ Group (defence S&T, closer Roke comp), Babcock International, and at the energetics-niche level, Hensoldt / Rheinmetall in Europe.

Investment thesis (3 bullets)

Structural rearmament tailwind with rare physical-supply moat in energetics. Norway/Scotland/Chicago facilities are sole/limited-source NATO suppliers of MCX, HMX, NLAW components, F-35 and space-launch initiators (e.g., Artemis II, Blue Origin, ULA), with a 12-year framework with Diehl (~€231m initial) and £917m segment order book providing visibility into 2027-28 2025-06 H1, 2026-06 H1.
Roke is a credible AI-receiver play within the group. Counter-drone CORTEXA launched with early Sweden/UK sales; £251m STORM missile-defence prime framework; CEMA, AI/ML and EW pipeline of £300m+ international; Vigil AI (CSAM detection trained on UK Home Office CAID) commercialising via Resolver/Kroll — and Roke targeting £250m revenue by 2028 vs. £175m FY25 2026-06 H1.
2028 step-change in operating leverage on a fixed-cost base. Management explicitly quantifies +£100m revenue / +£30m operating profit from capacity expansion (30% incremental margin) once Chicago, Scotland and Norway sites complete — net £110m of capex after £90m Norwegian grant funding, with Chicago/Scotland already substantially complete 2025-06 H1, 2026-06 H1.

Key risks (3 bullets)

Near-term margin compression and rising leverage during peak capex. H1 2026 underlying operating margin fell to 10.3% (from 11.9%), Sensors & Information margin halved on Roke under-utilisation and CORTEXA pre-production drag, net debt rose to £144.5m (1.47x EBITDA) and is guided to stay elevated through FY27 2026-06 H1.
UK delay risk and discontinued-operations noise. Delayed UK Defence Investment Plan publication has pushed Roke contract awards right; Alloy Surfaces closure required £8.3m H1 2026 charge after the disposal-as-going-concern thesis failed, and Tennessee legacy retirement caused £6.7m impairment — pattern of "one-offs" in C&E that complicates the underlying picture 2026-06 H1.
Valuation prices in execution. 26x trailing P/E for a defence industrial implies smooth delivery of the 2028 step-up; any further FX headwind, capacity-commissioning slippage, or US export-license disruption could de-rate the multiple toward QinetiQ-style mid-teens (inferred from peer trading levels).

Operating leverage

Chemring offers moderate, not extreme operating leverage. Today's group structure carries a fixed cost base of roughly £19m unallocated central costs plus large-asset energetics facilities; PP&E grew from £198m (FY21) to £388m (H1 2026), and depreciation runs at c.£24m p.a. C&E margins illustrate the leverage: 14.4% H1 2024 → 15.2% H1 2025 → 18.4% H1 2026 as orders flowed through fixed-cost Norwegian and Scottish plants 2026-06 H1. The cleanest observable inflection is management's own guidance: +£100m revenue → +£30m operating profit from 2028 capacity completion — a 30% incremental margin, materially above the current group margin of ~15%. If demand exceeds plan by 10-20% at these new sites, incremental drop-through likely improves further given the fixed-cost nature of high-grade explosives plants. Roke layers additional leverage: it is a high-fixed-cost engineering services / IP business where utilisation is the swing factor (visible in H1 2026 when "deliberately maintained operational capability" while waiting for the DIP halved segment margins). On the strict 0-100 scale, this earns mid-50s — real leverage exists, but it lacks the software-platform "1 unit revenue → 1 unit profit" dynamic the investor profile favours.

Value-trap signals

None identified. Order book at record highs, structural demand backdrop, no dividend cut (in fact +4%), £40m buyback in progress, balance sheet leverage manageable. Watch list (not yet trap signals): (i) repeated "non-underlying" exceptionals in C&E retirement/closures; (ii) discontinued Alloy required a strategic-review reversal; (iii) modest related-party-style IFRS 2 deferred consideration charges around Landguard/Geollect acquisitions, all properly disclosed.

Earnings vs. expectations

Across the period the pattern is consistent: management guides cautiously, references analyst consensus only loosely, and delivers in-line or marginally ahead. FY24 trading update (Oct 2024) flagged "in line with current range of analyst expectations" (£70.8-73.6m) and delivered £71.1m underlying op profit — slight miss to midpoint but within range 2024-10 trading update. FY23 was delivered in line with the £67m consensus 2023-11 trading update. FY22 exceeded "initial expectations" 2022-12 results. H1 2026 was described as "in line", though underlying operating profit fell 8% YoY — H2 weighted at 70% requires acceleration. Overall: more meets than beats; reliable but not a serial-beater stock.

Conviction

Conviction: 3 (moderate).

Anchors: (i) auditor-reviewed accounts with KPMG; (ii) order book gives unusually clear FY26-FY27 revenue visibility (91% / 81% cover); (iii) management has publicly anchored the 2028 step-up in specific £-figures, allowing a quantifiable bridge.
Limits: (i) FY26-27 will be a noisy "investment phase" with elevated net debt and depressed cash conversion — making P/E-based valuation harder to anchor; (ii) Roke margin trajectory is genuinely uncertain in the near term and is the swing factor for the AI-receiver thesis; a different methodology (sum-of-parts splitting out Roke at SaaS-like multiples vs. C&E at industrial multiples) could land 10-15% higher or lower.

Driver scoring (0-100)

ai_beneficiary 40 — Roke (c.35% of revenue) genuinely sells into AI-adjacent markets (EW, CEMA, AI/ML for national security, counter-drone with CORTEXA, Vigil AI for CSAM detection trained on Home Office data); however, the majority of the group (Countermeasures & Energetics) is unambiguously not an AI play. A partial beneficiary, not a pure-play.
operating_leverage 55 — High fixed-cost energetics facilities and capacity-constrained Roke services should drop incremental revenue through at ~30% margin (per management's own £100m/£30m bridge), but this is industrial-scale leverage, not platform/SaaS.
earnings_surprise_trend 55 — Repeatedly "in line"; pattern of meeting rather than beating.
cyclicality 35 — Defence is structurally less cyclical than typical industrials and currently in a multi-year rearmament cycle; some exposure to budget timing (Continuing Resolutions, UK DIP delays).
moat 70 — Sole-source positions (NASA, ULA, Blue Origin initiators; F-35 countermeasures), regulatory and qualification barriers in high-grade military explosives, multi-decade customer relationships, decade-plus contract frameworks.
leverage 40 — Net debt 1.47x EBITDA, peaking in FY26-27 then de-leveraging; well within covenants (3x limit), but heading the wrong direction during a fragile profit phase.
earnings_quality 55 — Cash conversion historically strong (rolling 95-108%) but H1 2026 only 42%; multiple "non-underlying" items each period; reconciliation is transparent but the gap between statutory and underlying widens repeatedly.
management_quality 70 — CEO Michael Ord has delivered consistent strategy execution; disciplined capital allocation (organic + bolt-on M&A + buyback + progressive dividend); candid on Alloy closure and Tennessee retirement.
growth_momentum 60 — Top-line +7% H1 2026, +13% FY22, +7% FY21; record order book growing, but underlying op profit -8% H1 2026 reflects investment drag.

Overall score: 440 / 1000

Rationale: Partial fit. The AI-receiver angle exists but is concentrated in Roke (~35% of revenue), not the dominant value driver. Valuation at ~26x trailing P/E already discounts the 2028 step-up — limited "right idea at a fair price" buffer. Operating leverage is real (incremental ~30% margin) but industrial, not platform-grade. Quality is decent, balance sheet is acceptable but levering up. Worth knowing about as a defence-cycle name with Roke optionality, but not a flagship pick for this strategy.